BG62032B1 - Антивирусна активна фармацевтична емулсия от масло във вода,съдържаща ацикловир или негова сол, или естер - Google Patents

Антивирусна активна фармацевтична емулсия от масло във вода,съдържаща ацикловир или негова сол, или естер Download PDF

Info

Publication number: BG62032B1
Authority: BG; Bulgaria
Prior art keywords: weight; acyclovir; water; cream; ester
Prior art date: 1992-09-09

Application number

BG99484A

Other languages

Bulgarian (bg)

English (en)

Other versions

BG99484A (bg

Inventor

Knud E. Gebhard-Hansen

Soren B. Pedersen

Karen Bjornsdottir

Bodil G. Lissau

Borge I. Alhede

Original Assignee

A/S Gea Farmaceutisk Fabrik

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-09-09

Filing date

1995-03-08

Publication date

1999-01-29

1995-03-08 Application filed by A/S Gea Farmaceutisk Fabrik filed Critical A/S Gea Farmaceutisk Fabrik

1995-12-29 Publication of BG99484A publication Critical patent/BG99484A/bg

1999-01-29 Publication of BG62032B1 publication Critical patent/BG62032B1/bg

Links

MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 title claims abstract description 86
229960004150 aciclovir Drugs 0.000 title claims abstract description 70
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims abstract description 37
150000002148 esters Chemical class 0.000 title claims abstract description 16
230000000840 anti-viral effect Effects 0.000 title claims abstract description 6
239000008251 pharmaceutical emulsion Substances 0.000 title claims abstract description 5
150000003839 salts Chemical class 0.000 title claims description 14
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 81
239000000839 emulsion Substances 0.000 claims abstract description 22
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 17
239000003960 organic solvent Substances 0.000 claims abstract description 10
239000004480 active ingredient Substances 0.000 claims abstract description 8
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims abstract description 6
UYTPUPDQBNUYGX-UHFFFAOYSA-N Guanine Natural products O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims abstract description 5
235000021355 Stearic acid Nutrition 0.000 claims abstract description 5
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims abstract description 5
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims abstract description 5
239000008117 stearic acid Substances 0.000 claims abstract description 5
229940057995 liquid paraffin Drugs 0.000 claims abstract description 4
239000003871 white petrolatum Substances 0.000 claims abstract description 4
YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 claims abstract description 3
SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 claims abstract description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 3
-1 2-hydroxyethoxy Chemical group 0.000 claims abstract 2
239000006071 cream Substances 0.000 claims description 80
229940074076 glycerol formal Drugs 0.000 claims description 35
239000008346 aqueous phase Substances 0.000 claims description 7
239000012071 phase Substances 0.000 claims description 7
239000002904 solvent Substances 0.000 claims description 5
239000000470 constituent Substances 0.000 claims description 2
235000019271 petrolatum Nutrition 0.000 claims description 2
239000000203 mixture Substances 0.000 abstract description 20
238000009472 formulation Methods 0.000 abstract description 5
IVSXFFJGASXYCL-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=NC=N[C]21 IVSXFFJGASXYCL-UHFFFAOYSA-N 0.000 abstract 1
229960004063 propylene glycol Drugs 0.000 abstract 1
235000013772 propylene glycol Nutrition 0.000 abstract 1
239000013589 supplement Substances 0.000 abstract 1
210000003491 skin Anatomy 0.000 description 39
230000035515 penetration Effects 0.000 description 26
238000012360 testing method Methods 0.000 description 16
229940107931 zovirax Drugs 0.000 description 16
206010015150 Erythema Diseases 0.000 description 15
238000011282 treatment Methods 0.000 description 14
231100000321 erythema Toxicity 0.000 description 12
239000000243 solution Substances 0.000 description 10
241001465754 Metazoa Species 0.000 description 9
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
208000015181 infectious disease Diseases 0.000 description 7
201000004624 Dermatitis Diseases 0.000 description 6
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
206010052428 Wound Diseases 0.000 description 6
208000027418 Wounds and injury Diseases 0.000 description 6
230000000694 effects Effects 0.000 description 6
229940068196 placebo Drugs 0.000 description 6
239000000902 placebo Substances 0.000 description 6
241000700198 Cavia Species 0.000 description 5
241000283973 Oryctolagus cuniculus Species 0.000 description 5
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 5
239000004202 carbamide Substances 0.000 description 5
150000001875 compounds Chemical class 0.000 description 5
239000007764 o/w emulsion Substances 0.000 description 5
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 4
230000001154 acute effect Effects 0.000 description 3
230000008859 change Effects 0.000 description 3
230000001186 cumulative effect Effects 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
239000003921 oil Substances 0.000 description 3
235000019198 oils Nutrition 0.000 description 3
239000008213 purified water Substances 0.000 description 3
230000009471 action Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
238000005259 measurement Methods 0.000 description 2
210000004877 mucosa Anatomy 0.000 description 2
238000012545 processing Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000012049 topical pharmaceutical composition Substances 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
BJUOZJRKUINRTO-UHFFFAOYSA-N C(C(C)O)O.C=O.OCC(O)CO Chemical compound C(C(C)O)O.C=O.OCC(O)CO BJUOZJRKUINRTO-UHFFFAOYSA-N 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
241000450599 DNA viruses Species 0.000 description 1
206010064503 Excessive skin Diseases 0.000 description 1
208000000903 Herpes simplex encephalitis Diseases 0.000 description 1
208000037018 Herpes simplex virus encephalitis Diseases 0.000 description 1
208000005100 Herpetic Keratitis Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
239000004909 Moisturizer Substances 0.000 description 1
201000010927 Mucositis Diseases 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
206010073938 Ophthalmic herpes simplex Diseases 0.000 description 1
239000005662 Paraffin oil Substances 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
206010040867 Skin hypertrophy Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
239000013543 active substance Substances 0.000 description 1
125000002015 acyclic group Chemical group 0.000 description 1
229940082500 cetostearyl alcohol Drugs 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
210000004087 cornea Anatomy 0.000 description 1
239000002537 cosmetic Substances 0.000 description 1
238000002316 cosmetic surgery Methods 0.000 description 1
239000006184 cosolvent Substances 0.000 description 1
230000018044 dehydration Effects 0.000 description 1
238000006297 dehydration reaction Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
241001493065 dsRNA viruses Species 0.000 description 1
238000004945 emulsification Methods 0.000 description 1
210000002615 epidermis Anatomy 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
230000006870 function Effects 0.000 description 1
239000011521 glass Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
201000010884 herpes simplex virus keratitis Diseases 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000008309 hydrophilic cream Substances 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
230000003902 lesion Effects 0.000 description 1
235000021388 linseed oil Nutrition 0.000 description 1
239000000944 linseed oil Substances 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
230000001333 moisturizer Effects 0.000 description 1
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
239000008385 outer phase Substances 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
230000037368 penetrate the skin Effects 0.000 description 1
230000035699 permeability Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000035807 sensation Effects 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
231100000475 skin irritation Toxicity 0.000 description 1
230000036556 skin irritation Effects 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
210000000434 stratum corneum Anatomy 0.000 description 1
OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
229940099259 vaseline Drugs 0.000 description 1
230000029663 wound healing Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

BG99484A 1992-09-09 1995-03-08 Антивирусна активна фармацевтична емулсия от масло във вода,съдържаща ацикловир или негова сол, или естер BG62032B1 (bg)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DK111392A DK169121B1 (da)	1992-09-09	1992-09-09	Antiviralt virksom farmaceutisk olie-i-vand-emulsion indeholdende 9-[(2-hydroxyethoxy)methyl]guanin (acyclovir) eller et salt eller en ester deraf
PCT/DK1993/000288 WO1994005258A1 (fr)	1992-09-09	1993-09-09	Emulsion pharmaceutique d'huile dans l'eau a action antivirale contenant de la 9-[(2-hydroxyethoxy)methyl]guanine (acyclovir) ou un sel ou ester de ladite substance

Publications (2)

Publication Number	Publication Date
BG99484A BG99484A (bg)	1995-12-29
BG62032B1 true BG62032B1 (bg)	1999-01-29

Family

ID=8101156

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG99484A BG62032B1 (bg)	1992-09-09	1995-03-08	Антивирусна активна фармацевтична емулсия от масло във вода,съдържаща ацикловир или негова сол, или естер

Country Status (27)

Country	Link
EP (1)	EP0662819B1 (fr)
JP (1)	JPH08501089A (fr)
AT (1)	ATE137113T1 (fr)
AU (1)	AU4945393A (fr)
BG (1)	BG62032B1 (fr)
BR (1)	BR9307024A (fr)
CA (1)	CA2142493A1 (fr)
CZ (1)	CZ284007B6 (fr)
DE (1)	DE69302396T2 (fr)
DK (1)	DK169121B1 (fr)
EE (1)	EE03088B1 (fr)
ES (1)	ES2086235T3 (fr)
FI (1)	FI112777B (fr)
GR (1)	GR3019984T3 (fr)
HR (1)	HRP931160B1 (fr)
HU (1)	HUT72606A (fr)
LT (1)	LT3056B (fr)
LV (1)	LV10912B (fr)
NO (1)	NO308234B1 (fr)
PL (1)	PL172663B1 (fr)
RO (1)	RO113306B1 (fr)
RU (1)	RU2128503C1 (fr)
SI (1)	SI9300469A (fr)
SK (1)	SK280119B6 (fr)
UA (1)	UA41897C2 (fr)
WO (1)	WO1994005258A1 (fr)
ZA (1)	ZA936661B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4416674C2 (de) *	1994-05-11	1997-01-30	Rentschler Arzneimittel	Topische Zubereitung enthaltend Aciclovir
ZA96525B (en) *	1995-02-06	1996-08-06	Astra Ab	Novel pharmaceutical compositions
US6440980B1 (en) *	1996-09-17	2002-08-27	Avanir Pharmaceuticals	Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
FR2753626B1 (fr) *	1996-09-20	1998-11-06	Centre International De Rech Dermatologiques Galderma Cird Galderma	Nouvelles compositions topiques sous forme d'emulsion fluide h/e a forte teneur en glycol pro-penetrant
AU2004202929B2 (en) *	1999-09-22	2006-11-23	B. Ron Johnson	Systems for agitated delivery of anti-infective compositions to treat disordered tissue such as cold sores
WO2005067941A1 (fr) *	2004-01-08	2005-07-28	Universidad De Concepcion	Formulation topique d’aciclovir
US9050365B2 (en) *	2004-04-19	2015-06-09	Strategic Science & Technologies, Llc	Transdermal delivery of beneficial substances effected by a hostile biophysical environment
US20050257718A1 (en) *	2004-05-22	2005-11-24	Engelhard Corporation	Natural Pearl in Butylene Glycol
WO2007121318A2 (fr) *	2006-04-12	2007-10-25	Emisphere Technologies, Inc.	Préparations destinées à l'administration d'insuline
WO2008006085A2 (fr) *	2006-07-07	2008-01-10	University Of Washington	Compositions et procédés pour prédire des inhibiteurs de cibles protéiques
US11684624B2 (en)	2009-06-24	2023-06-27	Strategic Science & Technologies, Llc	Treatment of erectile dysfunction and other indications
US12138268B2 (en)	2009-06-24	2024-11-12	Strategic Science & Technologies, Llc	Treatment of erectile dysfunction and other indications
EP3045171A1 (fr)	2009-06-24	2016-07-20	Strategic Science & Technologies, LLC	Composition topique
CN105920603B (zh)	2010-12-29	2022-02-11	战略科学与技术有限责任公司	勃起功能障碍和其它适应症的治疗
US9463180B2 (en)	2013-03-14	2016-10-11	Quadex Pharmaceuticals, Llc	Treatment of molluscum contagiosum
US9125911B2 (en)	2013-03-14	2015-09-08	Quadex Pharmaceuticals, Llc	Combined systemic and topical treatment of disordered tissues
US9549930B2 (en)	2013-03-14	2017-01-24	Quadex Pharmaceuticals, Llc	Combined systemic and topical treatment of disordered and/or prodromal stage tissue
FR3023718B1 (fr) *	2014-07-16	2018-10-12	Pierre Fabre Medicament	Compositions pharmaceutique et/ou cosmetique decontaminees par haute pression
GB201819418D0 (en)	2018-11-29	2019-01-16	Daniel Calladine Ltd	Anti-viral compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1523865A (en)	1974-09-02	1978-09-06	Wellcome Found	Purine compunds and salts thereof
GB2080106B (en) *	1980-07-18	1984-03-07	Weelcome Foundation Ltd	Acyclovin preparations

1992
- 1992-09-09 DK DK111392A patent/DK169121B1/da not_active IP Right Cessation
1993
- 1993-09-07 HR HR1113/92A patent/HRP931160B1/xx not_active IP Right Cessation
- 1993-09-09 UA UA95038210A patent/UA41897C2/uk unknown
- 1993-09-09 AU AU49453/93A patent/AU4945393A/en not_active Abandoned
- 1993-09-09 AT AT93919042T patent/ATE137113T1/de not_active IP Right Cessation
- 1993-09-09 SK SK291-95A patent/SK280119B6/sk unknown
- 1993-09-09 CZ CZ95599A patent/CZ284007B6/cs unknown
- 1993-09-09 SI SI9300469A patent/SI9300469A/sl unknown
- 1993-09-09 ES ES93919042T patent/ES2086235T3/es not_active Expired - Lifetime
- 1993-09-09 DE DE69302396T patent/DE69302396T2/de not_active Expired - Fee Related
- 1993-09-09 LT LTIP959A patent/LT3056B/lt not_active IP Right Cessation
- 1993-09-09 HU HU9500702A patent/HUT72606A/hu unknown
- 1993-09-09 CA CA002142493A patent/CA2142493A1/fr not_active Abandoned
- 1993-09-09 RU RU95110930A patent/RU2128503C1/ru active
- 1993-09-09 PL PL93307860A patent/PL172663B1/pl unknown
- 1993-09-09 JP JP6506765A patent/JPH08501089A/ja active Pending
- 1993-09-09 EP EP93919042A patent/EP0662819B1/fr not_active Expired - Lifetime
- 1993-09-09 WO PCT/DK1993/000288 patent/WO1994005258A1/fr not_active Ceased
- 1993-09-09 RO RO95-00478A patent/RO113306B1/ro unknown
- 1993-09-09 ZA ZA936661A patent/ZA936661B/xx unknown
- 1993-09-09 BR BR9307024A patent/BR9307024A/pt not_active Application Discontinuation
1994
- 1994-08-09 EE EE9400083A patent/EE03088B1/xx unknown
1995
- 1995-03-08 NO NO950895A patent/NO308234B1/no not_active IP Right Cessation
- 1995-03-08 BG BG99484A patent/BG62032B1/bg unknown
- 1995-03-08 FI FI951086A patent/FI112777B/fi active
- 1995-04-07 LV LVP-95-90A patent/LV10912B/en unknown
1996
- 1996-05-20 GR GR960401359T patent/GR3019984T3/el unknown

Also Published As

Publication number	Publication date
SK280119B6 (sk)	1999-08-06
CZ284007B6 (cs)	1998-07-15
DK111392D0 (da)	1992-09-09
FI951086A0 (fi)	1995-03-08
NO950895L (no)	1995-03-08
DK111392A (da)	1994-03-10
HRP931160B1 (en)	1999-04-30
EP0662819A1 (fr)	1995-07-19
UA41897C2 (uk)	2001-10-15
RU2128503C1 (ru)	1999-04-10
WO1994005258A1 (fr)	1994-03-17
JPH08501089A (ja)	1996-02-06
FI951086A7 (fi)	1995-03-08
EP0662819B1 (fr)	1996-04-24
LV10912A (lv)	1995-12-20
SK29195A3 (en)	1997-01-08
HUT72606A (en)	1996-05-28
NO950895D0 (no)	1995-03-08
LV10912B (en)	1996-08-20
DE69302396T2 (de)	1996-08-14
AU4945393A (en)	1994-03-29
RO113306B1 (ro)	1998-06-30
BG99484A (bg)	1995-12-29
ZA936661B (en)	1994-05-20
FI112777B (fi)	2004-01-15
EE03088B1 (et)	1998-06-15
HU9500702D0 (en)	1995-04-28
CA2142493A1 (fr)	1994-03-17
GR3019984T3 (en)	1996-08-31
ATE137113T1 (de)	1996-05-15
CZ59995A3 (en)	1995-09-13
HRP931160A2 (en)	1995-12-31
BR9307024A (pt)	1999-06-29
ES2086235T3 (es)	1996-06-16
LT3056B (en)	1994-10-25
LTIP959A (en)	1994-05-15
PL307860A1 (en)	1995-06-26
NO308234B1 (no)	2000-08-21
DE69302396D1 (de)	1996-05-30
PL172663B1 (pl)	1997-10-31
DK169121B1 (da)	1994-08-22
SI9300469A (en)	1994-03-31
RU95110930A (ru)	1997-03-27

Publication	Publication Date	Title
BG62032B1 (bg)	1999-01-29	Антивирусна активна фармацевтична емулсия от масло във вода,съдържаща ацикловир или негова сол, или естер
EP0677126B1 (fr)	1998-03-11	Compositions pharmaceutiques antivirales a usage local
US11628177B2 (en)	2023-04-18	Compositions and methods for deep dermal drug delivery
US20020127249A1 (en)	2002-09-12	Novel formulation for use in pain management
EP4364806A2 (fr)	2024-05-08	Formulation topique de diclofénac à taux d'absorption élevé
EP0247900A1 (fr)	1987-12-02	Préparation topique de méthotrexate pour le traitement de maladies hyperprolifératives épithéliales
JP3260370B2 (ja)	2002-02-25	トルナフタート含有液剤
CN114504549A (zh)	2022-05-17	生物素的水性凝胶剂及其制备方法和应用